Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
=== Setup of experiments === Cold fusion setups utilize an input power source (to ostensibly provide activation energy), a platinum group electrode, a deuterium or hydrogen source, a calorimeter, and, at times, detectors to look for byproducts such as helium or neutrons. Critics have variously taken issue with each of these aspects and have asserted that there has not yet been a consistent reproduction of claimed cold fusion results in either energy output or byproducts. Some cold fusion researchers who claim that they can consistently measure an excess heat effect have argued that the apparent lack of reproducibility might be attributable to a lack of quality control in the electrode metal or the amount of hydrogen or deuterium loaded in the system. Critics have further taken issue with what they describe as mistakes or errors of interpretation that cold fusion researchers have made in calorimetry analyses and energy budgets.
As of 2018, there are around 470 million pet dogs. Pet food production is responsible for 20–30% of the environmental impacts from animal production. It has been estimated that global greenhouse gas emissions from dog and cat dry food represents around 1.1%−2.9% of global emissions, an amount close to the total emissions of countries such as Mozambique or the Philippines. Like humans, dogs are omnivores. There is research on alternative protein sources for pet food including insects and algae. A life-cycle analysis of contemporary pet foods suggests wet foods for cats and dogs tend to have a larger impact than dry foods. It also suggests there are substantial opportunities for improvement in "all phases of the pet food life cycle, including formulation, ingredient selection, manufacturing processes" and so on.
== General sources == Aniszewski, Tadeusz (2007). Alkaloids: secrets of life. Amsterdam: Elsevier. ISBN 978-0-444-52736-3. Begley, Tadhg P. (2009). Encyclopedia of Chemical Biology. Vol. 10. Wiley. pp. 1569–1570. doi:10.1002/cbic.200900262. ISBN 978-0-471-75477-0. Brossi, Arnold (1989). The Alkaloids: Chemistry and Pharmacology. Academic Press. Dewick, Paul M. (2002). Medicinal Natural Products: A Biosynthetic Approach (Second ed.). Wiley. ISBN 978-0-471-49640-3. Fattorusso, E.; Taglialatela-Scafati, O. (2008). Modern Alkaloids: Structure, Isolation, Synthesis and Biology. Wiley-VCH. ISBN 978-3-527-31521-5. Grinkevich NI; Safronich LN, eds. (1983). The chemical analysis of medicinal plants (in Russian). Moscow: Vysshaya Shkola. Hesse, Manfred (2002). Alkaloids: Nature's Curse or Blessing?. Wiley-VCH. ISBN 978-3-906390-24-6. Knunyants, IL (1988). Chemical Encyclopedia. Soviet Encyclopedia. Orekhov, AP (1955). Chemistry alkaloids (Acad. 2nd ed.). Moscow.{{cite book}}: CS1 maint: location missing publisher (link) Plemenkov, VV (2001). Introduction to the Chemistry of Natural Compounds. Kazan.{{cite book}}: CS1 maint: location missing publisher (link) Saxton, J. E. (1971). The Alkaloids: A Specialist Periodical Report. London: The Chemical Society. Veselovskaya, N. B.; Kovalenko, A. E. (2000). Drugs. Moscow: Triada-X. Wink, M (2009). "Mode of action and toxicology of plant toxins and poisonous plants". Mitt. Julius Kühn-Inst. 421: 93–112x.
Sources: en.wikipedia.org
==== Appeal ==== In March 1996 Rose announced her intention to appeal against her sentence, contending that extensive press coverage had rendered witness testimony unreliable, that no physical evidence existed to attest she had participated in any of the murders, that the final instructions delivered by the judge to the jury had been biased in favour of the prosecution, and that undue weight had been given to the similar fact evidence introduced at her trial. This appeal was rejected by the Lord Chief Justice, Lord Taylor of Gosforth, who contended Rose had received a fair trial and efficient legal representation. In July 1997 then-Home Secretary Jack Straw subjected Rose to a whole life tariff, effectively denying her any possibility of parole. In October 2000, Rose again announced that she would appeal against her sentence via her solicitor, Leo Goatley. In September 2001 she announced her intention to abandon her appeals, stating she would never feel free even if released. She maintains her innocence in any of the murders.
=== Feeding and excretion === Cnidarians feed in several ways: predation, absorbing dissolved organic chemicals, filtering food particles out of the water, obtaining nutrients from symbiotic algae within their cells, and parasitism. Most obtain the majority of their food from predation but some, including the corals Hetroxenia and Leptogorgia, depend almost completely on their endosymbionts and on absorbing dissolved nutrients. Cnidaria give their symbiotic algae carbon dioxide, some nutrients, and protection against predators. Predatory species use their cnidocytes to poison or entangle prey, and those with venomous nematocysts may start digestion by injecting digestive enzymes. The "smell" of fluids from wounded prey makes the tentacles fold inwards and wipe the prey off into the mouth. In medusae, the tentacles around the edge of the bell are often short and most of the prey capture is done by "oral arms", which are extensions of the edge of the mouth and are often frilled and sometimes branched to increase their surface area. These "oral arms" aid in cnidarians' ability to move prey towards their mouth once it has been poisoned and entangled. Medusae often trap prey or suspended food particles by swimming upwards, spreading their tentacles and oral arms and then sinking. In species for which suspended food particles are important, the tentacles and oral arms often have rows of cilia whose beating creates currents that flow towards the mouth, and some produce nets of mucus to trap particles. Their digestion is both intra and extracellular.
Barbara, the US Supreme Court rules 5-4 that birthright citizenship is guaranteed under the Fourteenth Amendment and strikes down Trump's Executive Order 14160. Justice Kavanaugh concurs that the executive order should be struck down, but he believes that birthright citizenship is in federal statutory law rather than the Constitution. In West Virginia v. B.P.J. and Little v. Hecox, the US Supreme Court rules 6–3 that states may ban transgender athletes from participating in women and girls' sports. In National Republican Senatorial Committee v. FEC, the US Supreme Court rules 6–3 that federal limits on political parties for campaign finance violate the First Amendment's Free Speech Clause and strikes down those provisions in the Federal Election Campaign Act. Ford issues a recall order of over 741,000 vehicles, mainly F-150, Explorer, Expedition, Lincoln Aviator, and Navigator models, due to a transmission issue that may damage the park system.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.